1. Home
  2. NUAI vs CBIO Comparison

NUAI vs CBIO Comparison

Compare NUAI & CBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo New Era Energy & Digital Inc.

NUAI

New Era Energy & Digital Inc.

HOLD

Current Price

$6.74

Market Cap

633.1M

Sector

Energy

ML Signal

HOLD

CBIO

Crescent Biopharma Inc.

HOLD

Current Price

$17.52

Market Cap

557.8M

Sector

N/A

ML Signal

HOLD

Company Overview

Basic Information
Metric
NUAI
CBIO
Founded
N/A
2003
Country
United States
United States
Employees
5
44
Industry
Oil & Gas Production
Sector
Energy
Exchange
Nasdaq
Nasdaq
Market Cap
633.1M
557.8M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
NUAI
CBIO
Price
$6.74
$17.52
Analyst Decision
Buy
Strong Buy
Analyst Count
1
6
Target Price
$11.00
$26.67
AVG Volume (30 Days)
8.3M
239.8K
Earning Date
05-14-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$279.20
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.32
$8.72
52 Week High
$9.45
$27.41

Technical Indicators

Market Signals
Indicator
NUAI
CBIO
Relative Strength Index (RSI) 69.98 44.91
Support Level $3.71 $17.02
Resistance Level $7.59 $21.60
Average True Range (ATR) 0.72 1.41
MACD 0.15 -0.06
Stochastic Oscillator 87.33 37.75

Price Performance

Historical Comparison
NUAI
CBIO

About NUAI New Era Energy & Digital Inc.

New Era Energy & Digital Inc is engaged into a fully integrated energy supplier delivering next-gen digital infrastructure and power assets. The company provides turnkey solutions to speed up data center deployment and reduce costs. The company focuses on future-proofing infrastructure for hyperscale, enterprise, and edge operators. The company provide integrated energy and digital solutions to support accelerating AI infrastructure deployment and optimize data center investments.

About CBIO Crescent Biopharma Inc.

Crescent Biopharma Inc is a biopharmaceutical company developing novel therapeutics to treat solid tumors, led by CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody. Crescent's pipeline product CR-001 has the potential to deliver improved clinical efficacy and safety over pembrolizumab. CR-001 is a new molecular entity designed to replicate the functional properties of ivonescimab, a cooperative bispecific anti-PD-1/anti-VEGF antibody in development by Akeso Biopharma and Summit Therapeutics that delivered improved efficacy in a head-to-head Phase 3 clinical trial versus Keytruda in non-small cell lung cancer. The company focuses on advancing its second and third programs, CR-002 and CR-003, which are antibody drug conjugates (ADCs) against validated oncology targets.

Share on Social Networks: